Pipeline
We are a premier specialty pharmaceutical company providing innovative therapeutics to patients.
Our focus is on improving patient outcomes by developing and responsibly commercializing differentiated products through unique drug delivery systems for CNS disorders and pain. We broadly leverage our drug delivery technologies with partners for the benefit of physicians and patients in other therapeutic areas. We are building an organization that makes a difference in the lives of patients and our employees through the principles of ethical decision making, open communication and collaboration.
Pipeline:
| Product/Program | Pre-Clinical | Phase 1 | Phase 2 | Phase 3 | NDA | Commercial | Status |
| SUMAVEL DosePro | |||||||
| Acute migraine and cluster headache |
 |
|
|
|
|
|
Launched Jan 2010 |
| Delivery modifications including 4mg formulation | |
Targeting 2013 | |||||
| Covidien/Mallinckrodt co-promote partner | |||||||
| Zohydro ER | |||||||
| ER hydrocodone capsules for chronic pain |
 |
|
|
|
|
NDA Submitted May 2012 | |
| Seek potential co-promote partner on approval | |||||||
| RELDAY | |||||||
| Monthly SQ injection for schizophrenia |
|
|
IND Submitted May 2012 | ||||
| Seek ROW partner with Phase 1 extension study results | |||||||
| Undisclosed DosePro CNS Product Candidate | |||||||
| Undisclosed | |
||||||
 |
|
|
|
|
|
|
|